SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its position as a Bitcoin-native meme coin within the burgeoning Rune ecosystem. Discussions highlight the strong community, fair distribution, and the potential for $DOG to bridge Bitcoin culture with broader markets through its association with $CBLO. The community emphasizes holding through market volatility.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as traders discuss its potential as a privacy-focused alternative to Bitcoin, drawing comparisons to early BTC gains. Community members are pointing to recent investments from figures like the Winklevoss twins, as well as speculation around institutional adoption and regulatory environments favoring privacy coins. Some traders believe ZEC is inversely correlated to Bitcoin and are closely watching technical patterns for potential breakouts.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending amid discussions about its strategic shift towards AI and robotics, with the unveiling of the 'Iron' humanoid robot driving significant investor interest. The community is actively discussing the potential for XPEV to become a leader in physical AI, expanding beyond its current EV focus, with some comparing it favorably to Tesla. Bullish sentiment is also supported by strong delivery numbers and expansion into new global markets.

Memecoin on Injective taken over by the community.

Nonja

$NONJA is gaining traction as a meme coin on the Injective ($INJ) network, with community members highlighting its strong performance relative to $INJ and its robust, active community.  Discussion revolves around its potential for high returns, especially with the upcoming Injective EVM mainnet and potential ETFs, and the unique qualities of its NFT collections.  The community emphasizes $NONJA's strong fundamentals, burned liquidity, and status as a leading meme coin on the $INJ ecosystem.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIA is trending amid discussions about its recent earnings, investor day, and potential for a short squeeze. Community members are focused on the company's growth prospects in Africa and its path to profitability, with some expressing optimism about long-term targets and potential institutional investment. Bullish sentiment is fueled by perceived undervaluation and the stock's uncorrelated nature to other markets.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending amid market volatility and concerns about escalating US-China trade tensions, particularly following Trump's tariff threats. Community discussions revolve around potential support levels, oversold conditions, and whether the dip presents a buying opportunity or signals a deeper correction. Some traders are weighing potential forward splits and earnings from major tech companies like TSLA and NVDA, while others express concerns about an AI bubble and the broader economic impact of geopolitical factors.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending due to positive sentiment around a potential acquisition by Merck for $9.2B, which sent the stock soaring. The community is discussing the impact of the deal on options, what happens to shares post-acquisition, and whether a bidding war might further increase the acquisition price. Some investors are also looking at similar companies that may be acquisition targets.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions surrounding the release of Epstein files and their potential implications for Trump. The community is focused on speculation about Trump's connections and any efforts to suppress the release. Political divides are fueling the conversation, with some questioning motives and potential impacts.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as the community discusses Warren Buffett's firm taking a new multi-billion dollar stake in Google's parent company, Alphabet, signaling a bet on AI and growth stocks. This move has sparked debate, with some seeing it as a smart shift away from Apple, while others question the timing and Buffett's value investing principles. The investment comes amidst market context showing a bullish trend for Berkshire, although the stock is nearing overbought territory.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending as investors discuss its strong cash position, low share float, and Phase 3 trials targeting a significant patient population. The community is highlighting the potential for a squeeze, drawing comparisons to other stocks with similar ownership structures and catalysts. Some are noting potential institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 12-Month Low - Here's Why

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 12-Month Low - Should You Sell...

Anavex Shares Fall 35% After Negative EU Trend Vote On Alzheimer's Drug

(RTTNews) - Anavex Life Sciences Corp. (AVXL) dropped 35.15% to $3.69, down $2.00, after regulatory updates revealed that the Committee for Medicinal Products for Human Use - CHMP issued a negative...

<ul class="summary-bullets"><li>CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug.</li><li>However, the drug didn’t feature on the list of medicines for which applications were withdrawn following a meeting with the committee.&nbsp;</li><li>Anavex confirmed on Friday that it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation.</li></ul>Shares of Anavex Life Sciences (AVXL) slumped 45% in the premarket session on Friday after a European Medicines Agency (EMA) committee did not recommend a much-awaited approval for the company’s Alzheimer’s drug Blarcamesine.Retail investors were looking forward to the Committee for Medicinal Products for Human Use’s opinion on the drug after it placed Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from Nov. 10 to Nov.13, with the oral explanation held behind closed doors on Nov. 11.<h2 class="st-heading-2">CHMP Avoids Recommendation For Blarcamesine</h2>The CHMP <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025">released</a> its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine did not feature on the list. CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens chances for an EMA approval for the drug.However, the drug also didn’t feature on the list of medicines for which applications were withdrawn following a meeting with the committee.Anavex <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/14/3188222/29248/en/Anavex-Life-Sciences-Provides-Regulatory-Update-on-Blarcamesine-for-Early-Alzheimer-s-Disease.html">confirmed</a> on Friday that it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation. The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion.Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/AVXL"> AVXL stock </a>stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.AVXL stock is down 47% this year and by 29% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/avadel-gets-acquisition-proposal-from-lundbeck-weeks-after-inking-agreement-with-alkermes/cLPQetHRE4T">Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

AVXL Shares Slump Pre-Market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug

The CHMP released its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine was not included in the list.

Equity

The CHMP released its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine was not included in the list.


<ul class="summary-bullets"><li>The selloff comes as blarcamesine completed its oral explanation during the EMA’s Nov. 10–13 review window.</li><li>The therapy reached this stage after progressing through the Day-120 and Day-180 questions earlier this year.</li><li>Investors are watching for any CHMP update following recent data showing a slowing of cognitive decline.</li></ul>Anavex Life Sciences shares posted their steepest single-day drop in nearly two years on Thursday as investors braced for a key regulatory moment in Europe for its Alzheimer’s drug candidate, blarcamesine. The selloff comes as the therapy completed Oral Explanation Week at the European Medicines Agency (EMA), a step that typically signals regulators have unresolved questions late in the review.<h2 class="st-heading-2">Blarcamesine Completes EMA Oral Review Week</h2>The Committee for Medicinal Products for Human Use, or CHMP, placed blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from Nov. 10 to Nov.13, with the oral explanation held behind closed doors on Nov. 11. Oral explanations are not standard for smooth applications and they appear only when CHMP wants direct clarification before issuing an opinion, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/article/4842401-anavex-stock-nears-alzheimers-decision-with-limited-pipeline-offsets-atm-overhang">report</a> by Seeking Alpha.The drug’s EU dossier has progressed through the formal review stages over the past year, with Day-120 questions in April and Day-180 outstanding issues in September, at which point the CHMP noted that major objections remained. With the November session now concluded, investors are watching for any outcome in the committee’s published meeting highlights.<h2 class="st-heading-2">Recent Clinical Signals Added To Investor Focus</h2>In September, Anavex r<a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-rises-after-experimental-alzheimers-drug-slows-cognitive-decline/chwK3gqRdt9">eported new clinical findings</a> showing cognitive stabilization over 48 weeks in a precision-medicine subgroup of patients with early Alzheimer’s disease. Participants taking 30 mg once daily blarcamesine showed barely detectable cognitive decline across standard Alzheimer’s scales, and the company said the drug produced an 84.7% reduction in decline versus placebo on one neuropsychological test.The company is also testing blarcamesine in Parkinson’s disease dementia and Rett syndrome, expanding its pipeline beyond Alzheimer’s.<h2 class="st-heading-2">Analysts Still See A Possible Path To Conditional Approval</h2><a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-sparks-retail-banter-on-hopes-of-ema-conditional-nod-for-alzheimer-s-drug-big-pharma-tie-up/cLGP67oR3po">A report last month</a> from Spirit of the Coast Analytics said blarcamesine remains a candidate for conditional approval, noting that the Phase 2b/3 study had a modest sample size and missed one co-primary endpoint but showed statistically strong results on other measures, with supporting long-term durability data. The report highlighted that the EMA often opts for conditional approval for diseases with major unmet needs when safety is favorable.<h2 class="st-heading-2">Stocktwits Users Debate Path Forward</h2>On Stocktwits, retail sentiment for Anavex was ‘extremely bullish’ amid a 137% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:964/146;" src="https://news.stocktwits-cdn.com/avxl_ss_jpg_4b62ea4809.webp" alt="avxl ss.jpg" width="964" height="146"><figcaption>AVXL sentiment and message volume as of November 14 | Source: Stocktwits</figcaption></figure>One Stocktwits user argued that blarcamesine has an underappreciated advantage because it targets the same biological pathway that has long been pursued in the longevity and biohacking spaces, citing fasting, rapamycin, and other autophagy-related interventions. They suggested that the missed co-primary endpoint could still lead to conditional marketing authorization, with a follow-up trial reinforcing the outcome.<stembedurl>https://stocktwits.com/tby24/message/636164840</stembedurl>Another user said, “I think there is a 40% chance of an opinion, 60% chance we, among some others, are not mentioned at all.”<stembedurl>https://stocktwits.com/keyeaster/message/636164762</stembedurl>A third user said, “Actually, rejection is easy, EMA had everything they needed, it would have been very easy for them just looking at data and they would have said no before oral explanation. SO THERE IS ONLY ONE OPTION LEFT::APPROVAL.”<stembedurl>https://stocktwits.com/DK_72/message/636124008</stembedurl><a href="https://stocktwits.com/symbol/AVXL">Anavex’s stock</a> has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug?

The selloff comes as blarcamesine completed its oral explanation during the EMA’s Nov. 10–13 review window.

Anavex Life Sciences (NASDAQ:AVXL) Shares Down 6.7% - What's Next?

Anavex Life Sciences (NASDAQ:AVXL) Stock Price Down 6.7% - What's Next...

Stock Traders Purchase Large Volume of Anavex Life Sciences Put Options (NASDAQ:AVXL)

Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) was the recipient of some unusual options trading activity on Monday. Investors bought 10,341 put options on the company. This represents an...

<ul class="summary-bullets"><li>The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to EMA on human medicines, which the agency uses to approve or reject a drug.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December.&nbsp;</li><li>If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.</li></ul>Shares of Anavex Life Sciences (AVXL) were in the spotlight on Monday as retail investors contemplated the possibilities of a positive take from a European Medicines Agency (EMA) committee for the company’s Alzheimer’s drug Blarcamesine.The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to the agency on human medicines, which the agency uses to approve or reject a drug. On Monday, CHMP <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-10-13-november-2025_en.pdf">included</a> Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13. The oral explanation for Blarcamesine is scheduled for Nov. 11, 2025, at 2:00 p.m.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>A Stocktwits user is keenly awaiting the statement from Anavex.<stembedurl>https://stocktwits.com/DipperDoo/message/635619033</stembedurl>Another user expressed hope that the committee would be convinced of the drug’s importance following the oral presentation.<stembedurl>https://stocktwits.com/Cresskill198/message/635618141</stembedurl>AVXL shares were down 9% at the time of writing. On Stocktwits, overall retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/57;" src="data:image/png;base64,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" width="587" height="57" alt="AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Anavex’s Application</h2>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Last month, Spirit of the Coast Analytics <a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-sparks-retail-banter-on-hopes-of-ema-conditional-nod-for-alzheimer-s-drug-big-pharma-tie-up/cLGP67oR3po">noted</a> that Blarcamesine’s existing Phase 2b/3 data, while limited in sample size and missing one co-primary endpoint, showed statistically strong results and sustained efficacy over 192 weeks in long-term studies. According to the analyst, the company is “likely” positioned for approval by the EMA in Q4 2025 or Q1 2026. &nbsp;AVXL stock is down by 38% this year and by about 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ifrx-stock-soars-pre-market-after-experimental-drug-shows-promise-in-treating-chronic-skin-diseases/cLPcS62RE2E">IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee

On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 1-Year Low - What's Next?

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 1-Year Low - Here's Why...

<ul class="summary-bullets"><li>Spirit of the Coast Analytics said Anavex’s Alzheimer’s drug Blarcamesine is likely to gain conditional marketing authorization (CMA) from the European Medicines Agency, citing strong long-term efficacy data despite limited trial size.</li><li>The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization.</li><li>On Stocktwits, traders praised the analysis as “best in class,” with some predicting off-label use across other dementia types and urging patience for long-term gains.</li></ul>Anavex Life Sciences shares drew some retail chatter on Tuesday after a new report from Spirit of the Coast Analytics projected that the company’s lead Alzheimer’s drug, Blarcamesine, could secure conditional approval in Europe and attract a major pharmaceutical partner to accelerate commercialization.<h2 class="st-heading-2">EMA Conditional Approval Expected</h2>Spirit of the Coast Analytics&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sotcanalytics.com/update-compendium-2025#h.j7yb7yv7gs20">said</a> it believes Blarcamesine is “likely (though not definitive)” to receive conditional marketing authorization (CMA) from the European Medicines Agency (EMA). The report said the EMA often prefers granting conditional approval rather than outright denial for drugs addressing major unmet medical needs, particularly when data show large effect sizes.Analysts noted that Blarcamesine’s existing Phase 2b/3 data, while limited in sample size and missing one co-primary endpoint, showed statistically strong results and sustained efficacy over 192 weeks in long-term studies. The report emphasized that any conditional approval would reflect “incomplete” data, not doubts over validity.<h2 class="st-heading-2">Market Potential And Pricing Forecasts</h2>The report projected that Blarcamesine could capture up to 40% market share among early-stage Alzheimer’s patients across the U.S. and Europe, translating into tens of billions in potential revenue at peak.Spirit of the Coast estimated that the drug’s price could range between $10,000 and $18,200 per year in the U.S. and $8,000 and $14,000 in Europe, based on quality-adjusted life year (QALY) analysis. The analysts said the drug’s oral delivery, strong safety profile, and lack of complex monitoring requirements would support broad adoption and payer acceptance.<h2 class="st-heading-2">Partnership Pathway Viewed As Essential</h2>The report said Anavex “almost certainly requires a big-pharma partnership” to achieve its commercial potential. Analysts projected a possible multi-billion-dollar upfront payment with tiered royalty milestones under such a deal, noting that large pharmaceutical companies would likely seek to collaborate given the drug’s market opportunity and safety data.The report also said a partnership could accelerate regulatory engagement and manufacturing scale-up, allowing Anavex to compete more effectively against higher-priced monoclonal antibody therapies such as Leqembi and Kisunla.<h2 class="st-heading-2">Stocktwits Traders See Upside But Cautious On Long-Term Gains</h2>On Stocktwits, retail sentiment for Avanex was ‘bearish’ amid ‘normal’ message volume.One user called the analysis “best in class,” saying it highlighted “super-massive potential” for Blarcamesine, including off-label use in other dementias, and urged investors to “strap in” for the long term rather than selling early.<stembedurl>https://stocktwits.com/Veliger/message/633171391</stembedurl>Another user said the projections seemed “mathematically sound” but warned of a “fantasyland vibe,” estimating a 90% chance of approval and noting that retail investors’ gains may hinge on whether Anavex opts for a partnership or a buyout.<stembedurl>https://stocktwits.com/ItsThrillhouse/message/633175141</stembedurl><a href="https://stocktwits.com/symbol/AVXL">Avanex’s stock</a> has declined 13% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avanex’s stock has declined 13% so far in 2025. (Photo credit: Getty Images)

Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up

The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization.

Anavex Life Sciences (AVXL) on Thursday said that its investigational drug achieved its primary endpoint in a mid-stage trial and demonstrated safety and tolerability in adults with Schizophrenia.Shares of the company soared 9% in Thursday’s pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160275/29248/en/Anavex-Life-Sciences-Announces-Positive-Topline-Results-from-Phase-2-Study-of-ANAVEX-3-71-for-the-Treatment-of-Schizophrenia.html">said</a> that the safety profile of ANAVEX3-71 was consistent with previous studies in healthy volunteers, and no serious treatment-emergent adverse events were reported in the study.The company is evaluating the drug in the treatment of Schizophrenia, a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide. According to Anavex, the illness impacts 2.8 million people in the U.S. alone.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘high’ levels.Anavex also said on Thursday that encouraging trends were observed in biomarkers of Schizophrenia in the study that support continued development. This includes a reduced glial fibrillary acidic protein in patients receiving ANAVEX3-71 compared to placebo.GFAP is a marker of neuroinflammation, and a reduction in it suggests a potential disease-modifying effect that may become more pronounced with longer treatment durations, the company said.The company on Thursday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160281/29248/en/Anavex-Life-Sciences-Announces-Successful-Development-of-Once-Daily-Oral-Tablet-Formulation-for-the-ANAVEX-3-71-Program.html">announced</a> the successful development of a once-daily oral tablet formulation for the ANAVEX3-71 program. The tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing, it added.AVXL stock is down 16% this year but up approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-slashes-full-year-delivery-guidance-after-drop-in-q3-figures/chCrfpbR3OH">Rivian Slashes Full-Year Delivery Guidance After Drop In Q3 Figures</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

The company said that its investigational drug for Schizophrenia achieved its primary endpoint in a mid-stage trial.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVXL News

AVXLAnavex Life Sciences Corp